US2013330375A1PendingUtilityA1

Therapeutic Cancer Vaccine

55
Assignee: KHAMAR BAKULESH MAFATLALPriority: Feb 28, 2011Filed: Feb 27, 2012Published: Dec 12, 2013
Est. expiryFeb 28, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Bakulesh Mafatlal KhamarNirav Manojkumar DesaiChandreshwar Prasad ShuklaAvani Devenbhai DarjiIndravadan Ambalal Modi
A61K 2039/80A61P 35/00A61P 37/04A61K 2039/575A61K 9/0021A61K 2039/572A61K 2039/55594A61K 39/04A61K 2039/54A61K 39/0011A61K 39/00A61K 2039/5152A61K 35/12A61K 35/00A61K 38/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . Cancer vaccine composition comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein said antigen(s) is expressed on contacting said cancer cells with a p38 inducer, and where in said expressed antigen(s) are specific to allogenic organ/tissue to which said cancer cells belong. 
     
     
         2 . The composition as claimed in  claim 1  comprises the antigen expressing cells in the range of 10 4  to 10 9 . 
     
     
         3 . The composition as claimed in  claim 1  wherein when administered to a mammal, said composition elicits a cell mediated immune response specific to said tissue/organ to which said cancer cells belong. 
     
     
         4 . The composition as claimed in  claim 1  wherein when administered to a mammal, said composition elicits a humoral immune response specific to said tissue/organ to which said cancer cells belong. 
     
     
         5 . The composition as claimed in  claim 1  wherein the adjuvant is  Mycobacterium w.    
     
     
         6 . The composition as claimed in  claim 1  wherein the cancer cells are obtained from a patient and/or a cell repository. 
     
     
         7 . A method of treating cancer in a mammal comprising administering a to the mammal a therapeutically effective amount of the composition as claimed in  claim 1 . 
     
     
         8 . The method as claimed in  claim 1  wherein the cancer comprises homologous or heterologous cancer cells. 
     
     
         9 . The method as claimed in  claim 7  wherein the composition is a therapeutic vaccine composition comprising said cancer cells obtained from same or other mammal. 
     
     
         10 . The method as claimed in  claim 7  wherein said administration comprises parental routs. 
     
     
         11 . The method as claimed in  claim 7  wherein said administration comprises intradermal route.

Join the waitlist — get patent alerts

Track US2013330375A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.